Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Table 5 Summary of data published from phase III-IV trials on eribulin mesylate in metastatic breast cancer

Study (years)	Phase	Treatment	Patients (n)	OS (months)	PFS (months)	DOR (months)	OR (%)	Ref.
Cortes et al. (2011) [13]	III	Eribulin mesylate vs TPC	508 vs 254	13.1	3.7	3.9	13	[6]
Kaufman et al. (2012) [10]	III	Eribulin mesylate vs Capecitabine	554 vs 548	15.9	4.2	4.1	11	[10]
Ramaswami et al. (2014) [16]	IV	Eribulin mesylate	25	5.89	4.08	-	16	[16]
Poletti et al. (2014) [17]	IV	Eribulin mesylate	27	8	-	2.5	9	[17]
Gamucci et al. (2014) [18]	IV	Eribulin mesylate	133	14.3	4.4	5.2	21.1	[18]
Rasmussen et al. (2014) [19]	IV	Eribulin mesylate	44	-	-	-	12.5	[19]
Present study	IV	Eribulin mesylate	258	11.2	3.8	4.4	26

DOR Duration Of Response, OR Objective Response, OS Overall Survival, PFS Progression-free survival, TPC Treatment of physician’s choice